We are live on ! Find out more
TCM

Tekla Capital Management Portfolio holdings

AUM $2.56B
1-Year Est. Return 18.15%
This Fund
S&P 500
This Quarter Est. Return
+2.9%
1 Year Est. Return
+18.15%
3 Year Est. Return
+62.51%
5 Year Est. Return
+140.53%
10 Year Est. Return
+502.91%
AUM
$2.56B
AUM Growth
-$71.2M
Cap. Flow
-$99.6M
Cap. Flow %
-3.9%
Top 10 Hldgs %
40.31%
Holding
186
New
9
Increased
27
Reduced
32
Closed
20

Top Buys

Rank Stock Value
1
MRK icon
Merck
MRK
+$20M
2
REGN icon
Regeneron Pharmaceuticals
REGN
+$14.2M
3
AMGN icon
Amgen
AMGN
+$14.1M
4
PODD icon
Insulet
PODD
+$13.3M
5
BAX icon
Baxter International
BAX
+$11.2M

Top Sells

Rank Stock Value
1
LLY icon
Eli Lilly
LLY
+$31.7M
2
CI icon
Cigna
CI
+$22.5M
3
SGEN
Seagen Inc. Common Stock
SGEN
+$22.3M
4
BMY icon
Bristol-Myers Squibb
BMY
+$13.8M
5
SRPT icon
Sarepta Therapeutics
SRPT
+$13.7M

Sector Composition

Rank Sector Weight
1 Healthcare 96.28%
2 Real Estate 2.09%
3 Miscellaneous 1.37%
4 Industrials 0.26%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
CI icon
26
Cigna
CI
$76.3B
$27M 1.06%
96,339
-86,292
-47% -$22.5M
MCK icon
27
McKesson
MCK
$105B
$26.5M 1.04%
61,955
-4,500
-7% -$1.73M
ARGX icon
28
argenx
ARGX
$61.3B
$25.5M 1%
65,553
-22,757
-26% -$8.95M
HCA icon
29
HCA Healthcare
HCA
$91.8B
$25M 0.98%
82,403
-6,300
-7% -$1.75M
SYK icon
30
Stryker
SYK
$108B
$24.8M 0.97%
81,128
+9,550
+13% +$2.76M
IQV icon
31
IQVIA
IQV
$44.4B
$24.5M 0.96%
109,129
+46,012
+73% +$9.24M
ZTS icon
32
Zoetis
ZTS
$30.3B
$23.6M 0.92%
136,914
– –
CRL icon
33
Charles River Laboratories
CRL
$13B
$23.4M 0.91%
111,183
-6,900
-6% -$1.37M
SGEN
34
DELISTED
Seagen Inc. Common Stock
SGEN
$21.6M 0.85%
112,331
-112,332
-50% -$22.3M
SRPT icon
35
Sarepta Therapeutics
SRPT
$2.19B
$20.5M 0.8%
179,437
-106,216
-37% -$13.7M
NVO
36
Novo Nordisk
NVO
$188B
$19.9M 0.78%
245,554
+22,908
+10% +$1.87M
MOH icon
37
Molina Healthcare
MOH
$10.8B
$18.6M 0.73%
61,856
– –
JAZZ icon
38
Jazz Pharmaceuticals
JAZZ
$15.6B
$18.3M 0.72%
147,779
– –
BMRN icon
39
BioMarin Pharmaceuticals
BMRN
$12.5B
$18.3M 0.72%
210,789
-89,300
-30% -$8.4M
EW icon
40
Edwards Lifesciences
EW
$49.4B
$17.9M 0.7%
189,597
+18,451
+11% +$1.6M
HUM icon
41
Humana
HUM
$47.6B
$16.5M 0.64%
36,794
– –
APLS
42
DELISTED
Apellis Pharmaceuticals
APLS
$15.8M 0.62%
173,248
+38,124
+28% +$3.29M
BAX icon
43
Baxter International
BAX
$12.3B
$14.8M 0.58%
324,370
+257,058
+382% +$11.2M
EXEL icon
44
Exelixis
EXEL
$14.1B
$13.9M 0.54%
726,639
– –
NVS icon
45
Novartis
NVS
$263B
$13.7M 0.54%
136,225
– –
KRTX
46
DELISTED
Karuna Therapeutics, Inc. Common Stock
KRTX
$12.7M 0.5%
58,577
+5,125
+10% +$1.1M
PODD icon
47
Insulet
PODD
$9.66B
$12.6M 0.49%
+43,847
New +$13.3M
GH icon
48
Guardant Health
GH
$23.6B
$12.4M 0.48%
346,084
-126,100
-27% -$3.62M
ASND icon
49
Ascendis Pharma A/S
ASND
$15.8B
$12.4M 0.48%
138,791
+15,000
+12% +$1.31M
XBI icon
50
State Street SPDR S&P Biotech ETF
XBI
$10.4B
$12.3M 0.48%
147,677
– –
1
2
3 4 5

Similar funds

EST
EA Series Trust Newtown Square, Pennsylvania $2.84B AUM
VIA
Vident Investment Advisory Alpharetta, Georgia $2.9B AUM 24.67% 1-Year Est. Return
AWS
AJ Wealth Strategies New York $2.07B AUM 10.86% 1-Year Est. Return
JP
Jana Partners New York $1.34B AUM 4.95% 1-Year Est. Return
VCM
Vigilant Capital Management Portland, Maine $1.34B AUM 15.33% 1-Year Est. Return
FCFS
First Command Financial Services Fort Worth, Texas $1.06B AUM 10.74% 1-Year Est. Return
FCB
First Command Bank Fort Worth, Texas $1.06B AUM 10.74% 1-Year Est. Return
BWM
BerganKDV Wealth Management Bloomington, Minnesota $1,000M AUM 9.95% 1-Year Est. Return

Tekla Capital Management's Q2 2023 Portfolio in Review

As of Q2 2023, Tekla Capital Management held 186 positions worth $2.56B, down 2.7% from $2.63B the previous quarter. Its ten largest holdings account for 40% of the portfolio.

Tekla Capital Management withdrew a net $99.6M in Q2 2023, closing 20 positions and reducing 32 holdings. Its most notable exit was Travere Therapeutics, an estimated $9.41M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 96% of assets, down from 97% a quarter earlier, followed by Real Estate and Miscellaneous.

Against the trend, Tekla Capital Management opened a new position in Insulet worth $12.6M.

  • Tekla Capital Management's largest Q2 2023 buy was Insulet: 43,847 shares worth $12.6M.
  • Tekla Capital Management added most to Merck in Q2 2023, an estimated $20M increase.
  • Tekla Capital Management's biggest Q2 2023 reduction was Eli Lilly, cutting an estimated $31.7M.
  • Tekla Capital Management fully exited Travere Therapeutics in Q2 2023, selling an estimated $9.41M.
  • Tekla Capital Management's ten largest holdings make up 40% of its $2.56B portfolio in Q2 2023.
  • Tekla Capital Management opened 9 new positions and closed 20 in Q2 2023.
  • Tekla Capital Management's portfolio value fell 2.7% quarter-over-quarter to $2.56B.

Based on Tekla Capital Management's 13F filing for Q2 2023, filed 10 Aug 2023.